Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.44 |
| ▸ | CSF1R | P07333 | 3/20 | 0.43 |
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | MOK | Q9UQ07 | 2/20 | 0.43 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4939442 | 0.87 | BRAF (0.62) | BRAFMAPK14CSF1RKDRTNNI3K | |
| SCHEMBL4910940 | 0.85 | PLA2G2A (0.48) | CYP3A4CSF1RKDRMEN1KMT2A | |
| SCHEMBL4914944 | 0.85 | IGF1R (0.53) | CYP3A4TRPV1MOKMEN1KMT2A | |
| SCHEMBL15101655 | 0.83 | ABCG2 (0.53) | CYP3A4TRPV1MOKMEN1KMT2A | |
| SCHEMBL4905104 | 0.82 | IGF1R (0.60) | CYP3A4MEN1KMT2AIGF1R | |
| SCHEMBL4909868 | 0.80 | CYP3A4 (0.48) | CYP3A4TRPV1MOKMEN1KMT2A | |
| SCHEMBL15097296 | 0.80 | ABCG2 (0.63) | CYP3A4MOKMEN1KMT2A | |
| SCHEMBL4911277 | 0.80 | IGF1R (0.60) | CYP3A4TRPV1MOKMEN1KMT2A | |
| SCHEMBL4907465 | 0.79 | IGF1R (0.53) | CYP3A4MEN1KMT2AIGF1R | |
| SCHEMBL4912812 | 0.79 | KMT2A (0.49) | CYP3A4MOKMEN1KMT2AIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222297-B2 | e.g. 1-[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]-3-{4-[bis(2-chloroethyl)amino]phenyl}urea; anticarcinogenic agent; improved chemical stability and efficacy; brain tumor, breast cancer, colon cancer, leukemia, and neuroblastoma | ACADEMIA SINICA (TW) | 2012-07-17 | — | — | US | disclosed |
| US-20080171765-A1 | Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents | ACADEMIA SINICA (TW) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171765-A1 | Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents | WEE1, PCNA, ATIC | BRAF 859/4885MAPK14 2677/4885CYP3A4 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.